<DOC>
	<DOCNO>NCT01835847</DOCNO>
	<brief_summary>Accumulating evidence suggest role G protein-coupled inwardly-rectifying potassium ( GIRK ) channel pathology excitement nerve , medicine action ( like Tipepidine Hibenzate ) expect new curative medicine adolescent depression . The purpose research confirm effect carry additional dosage Tipepidine Hibenzate adolescent patient depression . If suggestion obtain research effect adolescent patient depression Tipepidine Hibenzate , contribute development medical treatment adolescent patient depression .</brief_summary>
	<brief_title>An Open Study Tipepidine Hibenzate Adolescent Patients With Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<criteria>[ Inclusion Criteria ] 1 . Depressive Episode ICD10 criterion . 2 . Patients treat antidepressant ( SSRI ; Fluvoxamine , Paroxetine , Sertraline , Escitalopram , SNRI ; Milnacipran , Duloxetine , NaSSa ; Mirtazapine ) , mood stabilizer ( Lithium , Sodium Valproate , Carbamazepine , Lamotrigine ) , atypical antipsychotic ( Risperidone , Olanzapine , Quetiapine , Perospirone , Aripiprazole , Blonanserin , Paliperidone ) treat . 3 . Patients stable 4weeks medication . [ Exclusion Criteria ] 1 . Patients previous hypersensitivity Tipepidine Hibenzate . 2 . Patients treat typical antipsychotic antidepressant except inclusion criterion 2. mood stabilizer except inclusion criterion 2 . 3 . Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>